References
- Costa R, Oliveira NG, Dinis-Oliveira RJ. Pharmacokinetic and pharmacodynamic of bupropion: integrative overview of relevant clinical and forensic aspects. Drug Metab Rev. 2019;51(3):293–313.
- Product Information: Wellbutrin ZL (bupropion hydrochloride extended-release tablets). GlaxoSmithKline, Research Triangle Park, NC 20093.
- Johnson JA, Lineberry CG, Ascher JA, et al. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry. 1991;52(11):450–456.
- Davidson J. Seizures and bupropion: a review. J Clin Psychiatry. 1989;50(7):256–261.
- Shepherd G. Adverse effects associated with extra doses of bupropion. Pharmacotherapy. 2005;25(10):1378–1382.
- Gummin D, Mowry JB, Beuhler MC, et al. 2019 Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th annual report. Clin Toxicol. 2020;58(12):1360–1541.
- Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clin Ther. 2005;27(11):1685–1695.
- Tripp AC. Bupropion, a brief history of seizure risk. Gen Hosp Psychiatry. 2010;32(2):216–217.
- Correia MS, Whitehead E, Cantrell FL, et al. A 10-year review of single medication double-dose ingestions in the nation's largest poison control system. Clin Toxicol. 2019;57(1):31–35.
- Pisani F, Oteri G, Costa C, et al. Effects of psychotropic drugs on seizure threshold. Drug Saf. 2002;25(2):91–110.
- Brown TB, Cofield SS, Iyer A, et al. Assessment of risk tolerance for adverse events in emergency department chest pain patients: a pilot study. J Emerg Med. 2010;39(2):247–252.
- Than M, Herbert M, Flaws D, et al. What is an acceptable risk of major adverse cardiac event in chest pain patients soon after discharge from the emergency department?: a clinical survey. Int J Cardiol. 2013;166(3):752–754.